JP2025509564A5 - - Google Patents
Info
- Publication number
- JP2025509564A5 JP2025509564A5 JP2024554777A JP2024554777A JP2025509564A5 JP 2025509564 A5 JP2025509564 A5 JP 2025509564A5 JP 2024554777 A JP2024554777 A JP 2024554777A JP 2024554777 A JP2024554777 A JP 2024554777A JP 2025509564 A5 JP2025509564 A5 JP 2025509564A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- nmod
- adc
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320629P | 2022-03-16 | 2022-03-16 | |
| US63/320,629 | 2022-03-16 | ||
| PCT/IB2023/052428 WO2023175483A1 (en) | 2022-03-16 | 2023-03-14 | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509564A JP2025509564A (ja) | 2025-04-11 |
| JP2025509564A5 true JP2025509564A5 (https=) | 2026-03-19 |
Family
ID=85776040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554777A Pending JP2025509564A (ja) | 2022-03-16 | 2023-03-14 | 抗ｔｒｏｐ２抗体－薬物コンジュゲート治療のためのスコアリング方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4493933A1 (https=) |
| JP (1) | JP2025509564A (https=) |
| KR (1) | KR20240165390A (https=) |
| CN (1) | CN118891525A (https=) |
| AU (1) | AU2023235490A1 (https=) |
| CA (1) | CA3255700A1 (https=) |
| IL (1) | IL315662A (https=) |
| WO (1) | WO2023175483A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026052764A1 (en) | 2024-09-06 | 2026-03-12 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody drug conjugate therapy |
| CN119986001B (zh) * | 2025-01-23 | 2026-04-07 | 中山大学孙逸仙纪念医院 | 试剂盒及其在预测trop2-adc疗效中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ATE198623T1 (de) | 1994-08-12 | 2001-01-15 | Myriad Genetics Inc | Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs |
| ATE201445T1 (de) | 1994-08-12 | 2001-06-15 | Myriad Genetics Inc | Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US7420040B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| IN2014DN06806A (https=) | 2012-02-10 | 2015-05-22 | Univ Maryland | |
| ITCH20120008A1 (it) * | 2012-05-16 | 2013-11-17 | Saverio Alberti | Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| US10241115B2 (en) * | 2013-12-10 | 2019-03-26 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue |
| AU2014371934B2 (en) * | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| IL310627B2 (en) | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| JP6980980B2 (ja) * | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| CN108601841A (zh) * | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性 |
| CN110461342A (zh) * | 2017-02-06 | 2019-11-15 | 诺华股份有限公司 | 预测对免疫疗法的反应的方法 |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
-
2023
- 2023-03-14 CN CN202380027572.6A patent/CN118891525A/zh active Pending
- 2023-03-14 AU AU2023235490A patent/AU2023235490A1/en active Pending
- 2023-03-14 IL IL315662A patent/IL315662A/en unknown
- 2023-03-14 WO PCT/IB2023/052428 patent/WO2023175483A1/en not_active Ceased
- 2023-03-14 JP JP2024554777A patent/JP2025509564A/ja active Pending
- 2023-03-14 CA CA3255700A patent/CA3255700A1/en active Pending
- 2023-03-14 EP EP23713763.3A patent/EP4493933A1/en active Pending
- 2023-03-14 KR KR1020247034328A patent/KR20240165390A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI847992B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| JP2023545359A5 (https=) | ||
| US12497465B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| TW202034959A (zh) | 抗體-藥物結合物與parp抑制劑之組合 | |
| JP2023539715A5 (https=) | ||
| JP2025509564A5 (https=) | ||
| TW201818973A (zh) | 利用投予抗her2抗體-藥物結合物之抗性癌的治療 | |
| JP2019500020A5 (https=) | ||
| TWI822822B (zh) | 抗體-藥物結合物之用途 | |
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| TW202327662A (zh) | 抗her2抗體藥物偶聯物及其組合物和用途 | |
| EP3271401A1 (en) | Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens | |
| JP7105304B2 (ja) | 尿路上皮がんの治療における抗ｈｅｒ２抗体－薬物コンジュゲートの使用 | |
| JP2023545096A5 (https=) | ||
| JP2024545428A5 (https=) | ||
| RU2013123792A (ru) | Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний | |
| JP2019524706A5 (https=) | ||
| JPWO2021251459A5 (https=) | ||
| CN118891525A (zh) | 用于抗trop2抗体-药物缀合物疗法的评分方法 | |
| TW201708407A (zh) | 螢光綴合物 | |
| TW202500194A (zh) | 用於癌症治療中患者選擇之ＣＥＡＣＡＭ５ ｍＲＮＡ分析 | |
| WO2025055589A1 (en) | Methods of treating cervical cancer using anti-her2 antibody-drug conjugates | |
| CN113754764B (zh) | 抗dog-1抗体、缀合物、药物组合物、药物制剂及其用途 | |
| CN120053679A (zh) | 一种靶向CD66c的抗体偶联药物及其在制备胃食管结合部癌治疗药物中的用途 | |
| JP2025503511A5 (https=) |